ALB001

ALB001

Indicaton

First personalized, orally available medicine against Rheumatoid arthritis

Therapeutic indications

Inflammation

Type of product

Small molecule

Table

Phase

Discovery
Available in

EU, US, Switzerland

You may also be interested in

AUP-16 (AUP1602-C)

AUP-16 multi-targeting therapy for chronic wounds (Diabetic Foot Ulcers...) shows 50% improvement vs placebo in Phase-2 RCT

Phase II completed

MV-010

MV-010 is an orally available recombinant bacterial enzyme formulated by an exclusively licensed platform to restore intestinal immune system homeostasis in inflammatory bowel disease (IBD).

Discovery

POL6014

Cystic fibrosis (CF) and other neutrophilic pulmonary diseases

Phase I started